The result is a paradox. Even before the HTA Review is formally concluded, announced, and implemented, the environment it was meant to reform has already worsened. Expectations that the review would stabilise or improve conditions now need to be recalibrated. The baseline has moved, and not in a favourable direction. …
To what extent does the system even see itself as bound by external review?
March 25, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials cite company consultation, system changes, and spending approvals to justify delay
June 4, 2026 - - Latest News -
An exchange that reveals the truth of a review that has now become a lot like 'Weekend at Bernie's'
June 3, 2026 - - Latest News -
Invitation confusion clouds Delphi studies and captures medical device sector
June 3, 2026 - - Latest News -
Patient voices take centre stage at the 2026 Patient's Choice Awards
June 3, 2026 - - Latest News